Drug Trial Radar · NCT03257241
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old
Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
582
Planned (sponsor's estimate)
Start
Jul 3, 2017
Primary completion
Apr 1, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Polish Adult Leukemia GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will include newly-diagnosed AML patients, not suffering acute promyelocytic leukemia; aged 18-60 years, who are eligible for standard induction chemotherapy. The patients will be randomized to one standard induction regimen (DAC or DA-90). At day seven after completion of induction, a bone marrow aspiration with MRD will be performed for an early evaluation of response to treatment. Patients without bone marrow blast reduction below 10% at day seven after induction will be given a second early induction course. Patients who do not achieve CR after two induction courses will be randomized to one of the standard salvage regimens (FLAG-IDA or CLAG-M). Postremission treatment intensity will be adjusted to risk group based on cytogenetic and molecular risk factors at diagnosis and AML biology (secondary AML, therapy related AML). Patients with a low risk of relapse will be allocated to consolidation, with three courses of high doses of Ara-C (HiDAC), or two courses of HiDAC with subsequent autologous stem cell transplantation. Intermediate- or high-risk patients will be referred for allogeneic stem cell transplantation, if they have a matched donor. Until transplantation, consolidation with HiDAC will be continued.
Conditions
- Acute Myeloid Leukemia
Interventions
A arm (DA-90)Drug
After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
B arm (DAC)Drug
After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
A arm (CLAG-M)Drug
Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment ("salvage") according to the CLAG- M or FLAG-IDA protocol.
B arm (FLAG-IDA)Drug
Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment ("salvage") according to the CLAG- M or FLAG-IDA protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Induction regimen efficacy (DA-90 vs DAC) - I inductionTime frame: On +7 day after chemotherpay
- Induction regimen efficacy (DA-90 vs DAC) - II inductionTime frame: On +28 day after chemotherapy or after complete morphology regeneration (if it occurs before day +28)
- Salvage regimen efficacy (CLAG-M vs FLAG-IDA) - I reinductionTime frame: On +28 day after chemotherapy or after complete morphology regeneration (if it occurs before day +28)
- Salvage regimen efficacy (CLAG-M vs FLAG-IDA) - II reinductionTime frame: On +28 day after chemotherapy or after complete morphology regeneration (if it occurs before day +28)
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Weill Cornell Medicine
New York, New York · Recruiting
Medical University of Bialystok Clinical Hospital
Bialystok, Poland · Recruiting
Markiewicz Memorial Oncology Center Brzozow
Brzozów, Poland · Recruiting
University Clinical Centre in Gdansk
Gdansk, Poland · Recruiting
Holycross Cancer Center
Kielce, Poland · Recruiting
Ludwik Rydygier Memorial Specialized Hospital
Krakow, Poland · Recruiting
Regional Specialised Hospital in Legnica
Legnica, Poland · Recruiting
Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology
Lodz, Poland · Recruiting
Independent Public University Hospital No. 1 in Lublin
Lublin, Poland · Recruiting
Clinical Hospital at the Karol Marcinkowski Medical University in Poznan
Poznan, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.